Serum Anti-14-3-3 Zeta Autoantibody as a Biomarker for Predicting Hepatocarcinogenesis.

Wang, Ting; Huang, Xue-Ying; Zheng, Su-Jun; Liu, Ye-Ying; Chen, Si-Si; Ren, Feng; Lu, Jun; Duan, Zhong-Ping; Liu, Mei

Wang, Ting; Huang, Xue-Ying; Zheng, Su-Jun; Liu, Ye-Ying; Chen, Si-Si; Ren, Feng; Lu, Jun; Duan, Zhong-Ping; Liu, Mei.

Afiliação

Wang T; Department of Respiratory and Infectious Diseases, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Huang XY; Department of Oncology, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Zheng SJ; First Department of Hepatology Center, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Liu YY; Department of Oncology, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Chen SS; Department of Oncology, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Ren F; Beijing Institute of Hepatology, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Lu J; Department of Oncology, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Duan ZP; Fourth Department of Hepatology Center, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Liu M; Department of Oncology, Beijing You'an Hospital, Capital Medical University, Beijing, China.

Front Oncol ; 11: 733680, 2021.

Article em En | MEDLINE | ID: mdl-34722278

Palavras-chave

14-3-3 zeta; SWATH-MS proteome technology; biomarker; hepatocarcinogenesis; premalignant liver disease

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies / Screening_studies Idioma: En Revista: Front Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China País de publicação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google